Overall, this study established the physiological and pathological significance of the EP300-AS1-PTBP1-PRMT5 axis in NSCLC progression, suggesting that EP300-AS1 mimetics or PTBP1 inhibition may represent promising therapeutic strategies for NSCLC. The gene discussed is PTBP1; the disease is non-small cell lung carcinoma.